Core Viewpoint - The report outlines a significant reduction in shareholding by Guoshou Chengda (Shanghai) Health Industry Equity Investment Center (Limited Partnership) in Jiahe Meikang (Beijing) Technology Co., Ltd., decreasing its stake to 10% due to financial needs and dilution from stock incentives [1][5]. Group 1: Shareholding Changes - The information disclosure obligor reduced its shareholding from 19,569,619 shares (14.19%) to 13,758,560 shares (10.00%) following a series of transactions [7][8]. - The reduction in shareholding was influenced by the company's issuance of restricted stock and stock options, leading to a dilution of the obligor's stake [5][9]. - The total share capital of Jiahe Meikang was adjusted from 137,877,502 shares to 137,585,598 shares as a result of these changes [8][10]. Group 2: Future Plans - The information disclosure obligor plans to reduce its holdings by up to 4,127,566 shares (3.00% of total shares) within the next 12 months through centralized bidding and block trading [5][6]. - As of the report date, the obligor's reduction plan remains incomplete, and future changes in shareholding are uncertain [5][11]. Group 3: Legal Compliance - The report confirms that the information disclosure obligor has complied with relevant laws and regulations, ensuring the accuracy and completeness of the disclosed information [2][12]. - The obligor has not engaged in any other transactions involving the company's shares in the six months prior to the report [10][13].

Group 1 - The company approved a share repurchase plan on June 19, 2025, with a budget between RMB 5 million and RMB 10 million, aiming to buy back its A-shares at a price not exceeding RMB 30 per share within 12 months [1][3]. - As of June 30, 2025, the company has not yet implemented the share repurchase [2]. - The company will adhere to relevant regulations and will make repurchase decisions based on market conditions, ensuring timely disclosure of progress to investors [3].

重要内容提示： | 回购方案首次披露日 | 2025/6/20 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 6 月 | 6 | 月 | 19 | 日~2026 | 年 | 18 日 | | 预计回购金额 | 500万元~1,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | | 0股 | | | | | | | 累计已回购股数占总股本比例 | | 0% | | | | | | | 累计已回购金额 | 0万元 | | | | | | | | 实际回购价格区间 | 0元/股~0元/股 | | | | | | | 一、回购股份的基本情况 证券代码：688105 证券简称：诺唯赞 公告编号：2025-030 南京诺唯赞生物科技股份有限公司 关于以集中竞价交易方式回购公司股份 ...

Core Viewpoint - The company announced a change in the designated sponsor representatives for its ongoing supervision during the initial public offering on the Sci-Tech Innovation Board, ensuring continuity in oversight of the use of raised funds [1]. Group 1 - The company received a letter from Huatai United Securities regarding the replacement of the sponsor representative for the ongoing supervision of its IPO on June 27, 2025 [1]. - Due to a job change, the original sponsor representative, Mr. Hong Jie Chao, is unable to continue his duties, leading to the appointment of Mr. Wang Jie Qiu as his replacement [1]. - The current sponsor representatives for the company's IPO supervision are now Mr. Wang Jie Qiu and Mr. Li Hao [1]. Group 2 - The company expressed gratitude to Mr. Hong Jie Chao for his contributions during the IPO and ongoing supervision period [1]. - Mr. Wang Jie Qiu has extensive experience in investment banking, having participated in multiple IPOs and bond issuances since 2011 [2]. - His previous projects include IPOs for Fengshan Group, Pengyao Environmental Protection, and several others, indicating a strong background in the industry [2].

证券代码：688105 证券简称：诺唯赞 公告编号：2025-029 南京诺唯赞生物科技股份有限公司 关于更换保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 华泰联合证券作为公司首次公开发行股票并在科创板上市的保荐机构及持 续督导机构，原委派洪捷超先生和李皓先生担任公司科创板首次公开发行持续督 导期的保荐代表人。现因洪捷超先生工作变动，无法继续履行持续督导职责。为 保证公司募集资金使用情况的持续督导工作有序进行，华泰联合证券现委派王杰 秋先生（简历详见附件）接替洪捷超先生，继续履行持续督导职责。 本次保荐代表人变更后，公司科创板首次公开发行股票的持续督导保荐代表 人为王杰秋先生和李皓先生。 公司董事会对洪捷超先生在公司首次公开发行股票并在科创板上市及持续 督导期间所做的工作表示衷心感谢！ 特此公告。 南京诺唯赞生物科技股份有限公司 董事会 2025 年 6 月 28 日 南京诺唯赞生物科技股份有限公司（以下简称"公司"）于 2025 年 6 月 27 日收到保荐机构华泰联合证券有限责任公司（以下简称"华泰 ...

Group 1 - Fujian Quanzhou has launched an instant settlement model for basic medical insurance funds to improve settlement efficiency and alleviate financial pressure on designated medical institutions [1] - The instant settlement reform establishes an efficient mechanism of "daily payment + monthly settlement" by compressing the settlement cycle and increasing payment frequency [1] Group 2 - Shanghai Pharmaceuticals announced that its subsidiary in Thailand received approval from the Thai FDA for the registration of Pregabalin capsules, which are used to treat various types of neuropathic pain and as an adjunct therapy for epilepsy [3] - Gilead Sciences announced that the FDA approved its injectable HIV-1 capsid inhibitor Yeztugo for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection in adults and adolescents weighing 35 kg or more [4] Group 3 - Haizheng Pharmaceutical plans to establish a joint venture for synthetic biology with its wholly-owned subsidiary, with a registered capital of 350 million yuan, aiming to support the professional and large-scale development of its synthetic biology business [6] - Nuo Vision announced a plan to repurchase shares worth between 5 million and 10 million yuan for employee stock ownership plans, with a repurchase price not exceeding 30 yuan per share [7] - Tiankang Biological's subsidiary Tiankang Pharmaceutical has completed the counseling acceptance for its public stock issuance and listing on the Beijing Stock Exchange [8] Group 4 - Baike Biological received approval from the National Medical Products Administration for clinical trials of its influenza virus split vaccine, which aims to provide new vaccination options for individuals aged 60 and above [10] - Dizhi Pharmaceutical announced the completion of patient enrollment for its global Phase III clinical study of its lung cancer targeted drug, which compares its drug with platinum-based chemotherapy for advanced non-small cell lung cancer [11] Group 5 - The FDA announced the launch of the "Commissioners National Priority Voucher" program to expedite new drug review times from approximately 10-12 months to 1-2 months for eligible companies [12] - Shengnuo Biological expects a net profit increase of 254% to 332% year-on-year for the first half of 2025, driven by strong performance in its peptide raw material business [12]

Industry Insights - The Ministry of Commerce of China is expediting the review of export license applications related to rare earths, emphasizing the importance of maintaining global supply chain stability and security [1] - The Huawei Developer Conference is taking place from June 20 to 22, showcasing innovations in HarmonyOS and AI, with a focus on Ascend computing power and the Harmony ecosystem [2] - The photovoltaic industry is expected to see a significant production cut in Q3, with operating rates projected to decrease by 10-15%, alongside strict audits on below-cost sales [4] - The gaming industry in Beijing is receiving support through 11 new measures aimed at fostering development, indicating a high level of industry vitality [7] - UTree Technology has confirmed the completion of its Series C financing, with a pre-investment valuation exceeding 10 billion yuan, signaling growth potential in the humanoid robotics sector [8] - The International Solid-State Battery Technology Conference has commenced, highlighting advancements in materials and smart equipment, with expectations for rapid growth in the solid-state battery market by 2027 [9] Macro Insights - China's Vice Premier He Lifeng stated that the country is an ideal, safe, and proactive investment destination for multinational companies, citing its large domestic market and robust industrial system [3]

Group 1 - The Ministry of Commerce will accelerate the review of export license applications related to rare earths, emphasizing the importance of maintaining global supply chain stability [1] - The Chinese photovoltaic industry is expected to see a significant reduction in production in Q3, with operating rates projected to decrease by 10%-15% compared to the previous quarter [2] - A video conference was held by three departments to strengthen safety management in the new energy vehicle sector, emphasizing the responsibility of manufacturers for product quality and safety [3] Group 2 - Yushu Technology has completed its C-round financing, led by major investors including China Mobile, Tencent, Alibaba, Ant Group, and Geely [4] - Beijing's government has introduced measures to support the gaming and esports industry, offering rewards up to 30 million yuan for companies enhancing R&D efficiency through AI and other technologies [5] - The gaming industry is receiving significant policy support from Beijing, with various financial incentives for hosting major esports events [7] Group 3 - The stock market indices have all declined, with the Shanghai Composite Index showing an increased possibility of forming a double top pattern [6] - Companies such as Giant Network and Changchun Technology are highlighted as potential beneficiaries of the favorable policies in the gaming sector [8] - Several companies have announced significant business developments, including H-share issuance plans and acquisitions in the semiconductor field [9]

Core Viewpoint - Multiple companies have announced significant developments, including investments, clarifications on business operations, and changes in control, which may present various investment opportunities and risks for stakeholders [2]. Company Announcements - **Hai Zheng Pharmaceutical** plans to establish a joint venture in synthetic biology with a registered capital of 350 million yuan, where Hai Zheng will contribute 260 million yuan, holding a 74.29% stake [3]. - **Jin Zhong Zi Jiu** clarified that its business scope remains unchanged despite media reports suggesting a shift away from liquor production, confirming that it will continue to focus on its core liquor business [4]. - **ST Gong Zhi** announced that its stock will resume trading on June 20, 2025, and enter a delisting period, with the last trading date expected to be July 10, 2025 [5]. - **Zhong Jing Electronics** confirmed that its production and operational conditions are normal, with no undisclosed significant matters [6]. - **Shan Jin International** is preparing for an overseas H-share issuance and listing on the Hong Kong Stock Exchange to enhance its global strategy [7]. - **Kang Da New Materials** intends to acquire at least 51% of Chengdu Zhongke Huamei Electronics to expand into the semiconductor integrated circuit sector [8]. - **Zhong Yan Chemical** agreed to a capital reduction for its subsidiary, which will result in it holding 100% of the subsidiary's equity, constituting a significant asset restructuring [9]. - **Tai Ji Co., Ltd.** announced a change in its actual controller to the Hubei Provincial State-owned Assets Supervision and Administration Commission, with stock resuming trading [10]. - **ST Yi Guo** plans to sell four Carrefour subsidiaries for 1 yuan, expecting to increase its net profit by approximately 572 million yuan, while focusing on its core home appliance business [11][12]. Performance Expectations - **Sheng Nuo Bio** anticipates a substantial increase in net profit for the first half of 2025, projecting a year-on-year growth of 253.54% to 332.10%, driven by strong performance in its peptide raw material business [13]. Share Buyback - **Nuo Wei Zan** intends to repurchase shares worth between 5 million and 10 million yuan to implement employee stock ownership plans, with a maximum repurchase price of 30 yuan per share [14]. Major Contracts - **Sai Sheng Pharmaceutical** signed a technology transfer contract for a new drug project with a total transaction amount of 20 million yuan, which will enhance its capabilities in the protein/antibody drug platform [15].

1、习近平同俄罗斯总统普京通电话 重点就中东局势交换意见 重要程度：★★★★★ 6月19日下午，国家主席习近平同俄罗斯总统普京通电话，重点就中东局势交换意见。 普京通报了俄方对当前中东局势的看法，表示目前局势还在快速发展，俄方愿同中方保持密切沟通，共同 为局势降温作出积极努力，维护地区和平稳定。 习近平阐述了中方的原则立场并表示，当前中东局势很危急，再次印证世界进入新的动荡变革期。如果冲 突进一步升级，不仅冲突双方将遭受更大损失，地区国家也将深受其害。习近平强调，中方愿继续同各方 加强沟通协调，凝聚合力、主持公道，为恢复中东地区和平发挥建设性作用。 2、何立峰：中国是跨国公司理想安全有为的投资目的地 重要程度：★★★★ 第六届跨国公司领导人青岛峰会19日开幕。中共中央政治局委员、国务院副总理何立峰出席开幕式并致 辞。何立峰指出，中国拥有超大规模国内市场和全球最完备产业体系，展现出强大经济发展韧性和增长潜 力，是跨国公司理想、安全、有为的投资目的地。 3、商务部最新发声!谈稀土出口、中欧经贸关系等 重要程度：★★★★ 6月19日下午，商务部召开例行新闻发布会。发布会上，新闻发言人何亚东谈到稀土相关出口问题时表 ...